MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States.

"The addition of Scot to our sales and distribution team provides our company a wealth of leadership and veterinary sales experience," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "One of our primary objectives to achieve success in our company is to expand sales; we believe that the vast insight and expertise Scot brings to the PetVivo Sales Team puts us in an excellent position to meet this objective"

Scot Cave brings to PetVivo more than 25 years of animal health sales and management experience. He brings a wealth of leadership experience which began with his professional career as an officer in the United States Army. Most recently Scot achieved success while working as a Regional Veterinary Account Manager with our distribution partner Covetrus. Additionally, Scot's career has provided valuable sales experience in veterinary industry positions with veterinary companies, such as Medivet, KindredBio and Merck, to just name a few. Scot has a Bachelor of Science degree in Biology, with a minor in General Science/Chemistry from Ferris State University in Big Rapids, Michigan.

"Joining PetVivo as a new Field Veterinary Business Development Manager is an incredible opportunity for me to continue my passion, leverage my industry knowledge, and positively impact the quality of life for horses and companion animals. I am excited and honored to be a part of this valuable team," said Scot Cave. "I am thankful for the opportunity to be able to promote and sell a veterinary medical device that addresses joint related afflictions caused by the loss or damage of cartilage rather than simply treating the symptoms of pain and inflammation. I truly believe Spryng has the ability to improve the medical outcomes of animals suffering from lameness and other joint related afflictions, such as osteoarthritis, thereby enhancing the lives of animals and their owners."

About PetVivo Holdings

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.

PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng with OsteoCushion Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.

For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.

Disclosure Information

PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.

Forward-Looking commercial Statements

The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact